- Home
- TNON vs MYNZ Comparison
TNON vs MYNZ Comparison
Compare TNON & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNON | MYNZ |
|---|---|---|
| Founded | 2012 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 10.2M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TNON | MYNZ |
|---|---|---|
| Price | $0.67 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $14.00 |
| AVG Volume (30 Days) | 91.1K | ★ 442.3K |
| Earning Date | 03-19-2026 | 09-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,233,000.00 | $659,935.00 |
| Revenue This Year | $19.56 | N/A |
| Revenue Next Year | $71.06 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.67 | $0.92 |
| 52 Week High | $5.85 | $8.20 |
Technical Indicators
Market Signals| Indicator | TNON | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 19.23 | 37.01 |
| Support Level | $0.67 | $1.15 |
| Resistance Level | $0.97 | $1.37 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 3.33 | 0.80 |
Price Performance
Historical ComparisonAbout TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.